KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Gains from Sales and Divestitures (2023 - 2025)

Globus Medical posted quarterly Gains from Sales and Divestitures of $117000.0 for Q3 2025, down 66.86% year-on-year from $353000.0 in Q3 2024, and up 485.0% on a QoQ basis from $20000.0 in Q2 2025.

Globus Medical (GMED) has 3 years of Gains from Sales and Divestitures data on file, last reported at $117000.0 in Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures fell 66.86% year-over-year to $117000.0; the trailing twelve-month figure through Sep 2025 stood at $117000.0 (down 66.86% YoY), and the FY2024 full-year result was $367000.0, up 18250.0% from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 stood at $117000.0, up from $20000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $432000.0 in Q3 2023 and bottomed at $2000.0 in Q4 2023.
  • The 3-year median for Gains from Sales and Divestitures is $117000.0 (2025), against an average of $188222.2.
  • The widest annual swing landed in 2024, when Gains from Sales and Divestitures surged 18250.0%; it then tumbled 67.33% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $2000.0 in 2023, then soared by 18250.0% to $367000.0 in 2024, then tumbled by 68.12% to $117000.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $117000.0 (Q3 2025), $20000.0 (Q2 2025), and $98000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Globus Medical 10.79 Bn 10.16 Bn 525.79 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 117,000.00
Sep 30, 2025 117,000.00
Jun 30, 2025 20,000.00
Jun 30, 2025 20,000.00
Mar 31, 2025 98,000.00
Mar 31, 2025 98,000.00
Dec 31, 2024 367,000.00
Dec 31, 2024 367,000.00
Sep 30, 2024 353,000.00
Sep 30, 2024 353,000.00
Jun 30, 2024 5,000.00
Jun 30, 2024 5,000.00
Mar 31, 2024 300,000.00
Mar 31, 2024 300,000.00
Dec 31, 2023 2,000.00
Dec 31, 2023 2,000.00
Sep 30, 2023 432,000.00
Sep 30, 2023 432,000.00